JP2022521299A5 - - Google Patents

Info

Publication number
JP2022521299A5
JP2022521299A5 JP2021549275A JP2021549275A JP2022521299A5 JP 2022521299 A5 JP2022521299 A5 JP 2022521299A5 JP 2021549275 A JP2021549275 A JP 2021549275A JP 2021549275 A JP2021549275 A JP 2021549275A JP 2022521299 A5 JP2022521299 A5 JP 2022521299A5
Authority
JP
Japan
Prior art keywords
composition according
composition
fusion molecule
tumor
negative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021549275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521299A (ja
JP7544728B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019135 external-priority patent/WO2020172482A2/en
Publication of JP2022521299A publication Critical patent/JP2022521299A/ja
Publication of JP2022521299A5 publication Critical patent/JP2022521299A5/ja
Priority to JP2024077877A priority Critical patent/JP2024097962A/ja
Application granted granted Critical
Publication of JP7544728B2 publication Critical patent/JP7544728B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021549275A 2019-02-22 2020-02-21 Pd-l1陰性腫瘍を治療するためのcd80細胞外ドメイン-fc融合タンパク質 Active JP7544728B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024077877A JP2024097962A (ja) 2019-02-22 2024-05-13 Pd-l1陰性腫瘍を治療するためのcd80細胞外ドメイン-fc融合タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962809319P 2019-02-22 2019-02-22
US62/809,319 2019-02-22
US201962815249P 2019-03-07 2019-03-07
US62/815,249 2019-03-07
PCT/US2020/019135 WO2020172482A2 (en) 2019-02-22 2020-02-21 Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077877A Division JP2024097962A (ja) 2019-02-22 2024-05-13 Pd-l1陰性腫瘍を治療するためのcd80細胞外ドメイン-fc融合タンパク質

Publications (3)

Publication Number Publication Date
JP2022521299A JP2022521299A (ja) 2022-04-06
JP2022521299A5 true JP2022521299A5 (cg-RX-API-DMAC7.html) 2023-02-28
JP7544728B2 JP7544728B2 (ja) 2024-09-03

Family

ID=70057229

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549275A Active JP7544728B2 (ja) 2019-02-22 2020-02-21 Pd-l1陰性腫瘍を治療するためのcd80細胞外ドメイン-fc融合タンパク質
JP2024077877A Pending JP2024097962A (ja) 2019-02-22 2024-05-13 Pd-l1陰性腫瘍を治療するためのcd80細胞外ドメイン-fc融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024077877A Pending JP2024097962A (ja) 2019-02-22 2024-05-13 Pd-l1陰性腫瘍を治療するためのcd80細胞外ドメイン-fc融合タンパク質

Country Status (10)

Country Link
US (1) US12589132B2 (cg-RX-API-DMAC7.html)
EP (1) EP3927365B1 (cg-RX-API-DMAC7.html)
JP (2) JP7544728B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210130706A (cg-RX-API-DMAC7.html)
AU (1) AU2020224137B2 (cg-RX-API-DMAC7.html)
ES (1) ES2989890T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021010061A (cg-RX-API-DMAC7.html)
SG (1) SG11202107966TA (cg-RX-API-DMAC7.html)
TW (1) TW202045544A (cg-RX-API-DMAC7.html)
WO (1) WO2020172482A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
CN110546509A (zh) 2017-04-28 2019-12-06 戊瑞治疗有限公司 用cd80细胞外结构域多肽进行治疗的方法
AU2020224137B2 (en) 2019-02-22 2026-01-08 Five Prime Therapeutics, Inc. CD80 extracellular domain-Fc fusion proteins for treating PD-L1 negative tumors
MX2021013272A (es) 2019-05-03 2021-11-17 Five Prime Therapeutics Inc Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.
WO2021092084A1 (en) * 2019-11-04 2021-05-14 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
CN112326961B (zh) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US5858776A (en) 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US6130316A (en) 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
EP1025856A3 (en) 1994-03-08 2002-10-16 Dana-Farber Cancer Institute Methods for modulating T Cell unresponsiveness
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1997047732A2 (en) 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6491925B2 (en) 1996-08-15 2002-12-10 Emory University Compositions and methods for cancer prophylaxis and/or treatment
EP0988321A2 (en) 1997-06-20 2000-03-29 Innogenetics N.V. B7-binding molecules for treating immune diseases
US7011833B1 (en) 1999-05-06 2006-03-14 Genetics Institute, Inc. Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
US7064111B1 (en) 1999-10-05 2006-06-20 Georgetown University Use of soluble costimulatory factor for tumor immuno-gene therapy
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
AU2002368044A1 (en) 2001-06-22 2004-04-19 Maxygen, Inc. Co-stimulatory molecules
WO2003039486A2 (en) 2001-11-09 2003-05-15 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
KR100976076B1 (ko) 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
NZ545314A (en) 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
CN101072578A (zh) 2004-10-29 2007-11-14 南加州大学 用共刺激分子的联合癌症免疫疗法
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
WO2008037080A1 (en) 2006-09-29 2008-04-03 Universite De Montreal Methods and compositions for immune response modulation and uses thereof
CA2682027A1 (en) 2007-03-28 2008-10-02 Biogen Idec Inc. Modulation of tumor microenvironment
US20100189716A1 (en) 2007-03-28 2010-07-29 Biogen Idec Inc. Treatment of hodgkins lymphoma
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2009089149A1 (en) 2008-01-03 2009-07-16 The Johns Hopkins University B7-h1 (cd274) antagonists induce apoptosis of tumor cells
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
RU2657440C2 (ru) 2011-06-30 2018-06-13 Джензим Корпорейшн Ингибиторы т-клеточной активации
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
WO2013116686A1 (en) 2012-02-02 2013-08-08 Massachusetts Institute Of Technology Methods and products related to targeted cancer therapy
EP2809345A4 (en) 2012-02-03 2015-11-25 Univ Emory IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
EP2969009B1 (en) 2013-03-15 2018-11-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
EP3470081A1 (en) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
EP3087099A4 (en) 2013-12-23 2017-07-19 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
WO2016044189A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
WO2016147182A1 (en) 2015-03-16 2016-09-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Isolated peptides derived from the b7 ligand dimer interface and uses thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017042816A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Ablation of perforin positive dendritic cells in cancer treatment
EP3350206A1 (en) 2015-09-14 2018-07-25 Alpine Immune Sciences, Inc. Tunable variant immunoglobulin superfamily domains and engineered cell therapy
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
US11155622B2 (en) 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
CA3014458A1 (en) 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
HUE064857T2 (hu) 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
SG11201808552XA (en) 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
US10906957B2 (en) 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CN110546509A (zh) 2017-04-28 2019-12-06 戊瑞治疗有限公司 用cd80细胞外结构域多肽进行治疗的方法
KR20210049814A (ko) 2018-08-29 2021-05-06 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 fc 융합 단백질 투약 요법
AU2020224137B2 (en) 2019-02-22 2026-01-08 Five Prime Therapeutics, Inc. CD80 extracellular domain-Fc fusion proteins for treating PD-L1 negative tumors
MX2021013272A (es) 2019-05-03 2021-11-17 Five Prime Therapeutics Inc Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.

Similar Documents

Publication Publication Date Title
JP2020502059A (ja) Egfrまたはher2のエクソン20変異を有するがん細胞に対する抗腫瘍活性を有する化合物
CN110621787A (zh) 用于癌症的诊断和治疗方法
WO2016154412A2 (en) Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer
CN113939309A (zh) 使用sEphB4-HSA融合蛋白治疗癌症
US20220054614A1 (en) Inhibition of asph expressing tumor growth and progression
CA3193421A1 (en) Lag-3 antagonist therapy for hepatocellular carcinoma
CA3196496A1 (en) Lag-3 antagonist therapy for lung cancer
TW202045544A (zh) 用於治療PD-L1陰性腫瘤之CD80胞外結構域Fc融合蛋白
CA3201519A1 (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
US20190269729A1 (en) Modified natural killer cells for the treatment of cancer
US20230058305A1 (en) Methods and compositions for treating myc-driven cancers
TW202440154A (zh) 用pd-1軸結合拮抗劑及rna疫苗治療胰臟癌之方法
KR20250123912A (ko) 폐암에 대한 병용 요법
IL322997A (en) Ligand-dependent co-repressor (LCOR) mutations and their uses
US20240156911A1 (en) Lung-cancer specific t cell dysfunction
EP4711380A1 (en) Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy
HK40121936A (en) Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
Nwizu et al. Crizotinib: ALK/Met inhibitor, oncolytic
WO2025245489A1 (en) Treatment of tumors in subjects having fgl-1 positive samples
WO2024052532A1 (en) Anti-gdf15 antibody used in a combination treatment of specific patient groups and a dosage regimen for the treatment of cancer
WO2025064873A2 (en) Compositions and methods for treating cancer
Ioakeim et al. Emerging molecular targets in Metastatic Colorectal Cancer
Stringer et al. American Society of Hematology 60th Annual Meeting and Exposition. San Diego, California, USA-December 1-4, 2018
CN118891062A (zh) 用米非司酮阻断糖皮质激素受体使胰腺癌对免疫疗法敏感
HK40019960A (en) Diagnostic and therapeutic methods for cancer